Bayer Stock Balances a German Drug Pricing Hit with Apollo’s €3B Vote of Confidence
Published on 07/12/2026 at 08:54 | Redaktion boerse-global.de
Bayer shares closed Friday at €50.18, shedding 1.03% after the Bundestag passed legislation that sharply raises the mandatory discount on patented medicines. The law, approved by 318 votes to 284, lifts the manufacturer rebate from a floating 7% to a fixed 15.5% — an 8.5 percentage-point increase — and raises the discount on vaccines to 9%. The Bundesrat waived its right to call a mediation committee, clearing the way for the measure to take effect.
The immediate share-price dip interrupted a blistering rally that has seen the stock gain 42.60% over the past month and 80.99% over twelve months. Even after Friday’s setback, Bayer trades near the 52-week high of €53.86 set on July 3, powered by a series of positive catalysts that now sit uncomfortably alongside the new German regulatory headwind.
Apollo’s Bet and the Glyphosat Legal Calendar
The most dramatic catalyst came earlier in the week, when Apollo-managed funds agreed to take a minority stake in a newly formed entity holding Bayer’s long-acting reversible contraception (LARC) business, injecting €3 billion in equity. Bayer retains majority ownership and full operational control, describing the transaction as a balance-sheet-strengthening move to shore up liquidity for upcoming bond maturities and potential payments from the ongoing US glyphosate litigation.
That litigation itself has shown signs of easing. The US Supreme Court reduced Bayer’s litigation risk in a June 2026 ruling, and the company has transferred its US glyphosate operations into a new unit called Ruveon LLC to gain strategic flexibility. However, the final approval hearing for the multibillion-dollar glyphosate settlement has been postponed from early July to August 19 — a date that now looms large on investors’ calendars.
Should investors sell immediately? Or is it worth buying Bayer?
Adding a further twist, Bayer’s Monsanto subsidiary filed a petition with US authorities seeking anti-dumping duties on glyphosate imports from China, arguing that Chinese producers are unfairly depressing prices. US agricultural groups immediately pushed back, warning that higher tariffs would ultimately hurt farmers.
Technical Strains and a Quiet Period Ahead
The breakneck pace of the rally has pushed Bayer’s shares into technically overbought territory. The 14-day relative strength index stands at 70.4, a classic warning signal. The stock trades 24.95% above its 50-day moving average and 33.18% above its 200-day moving average — distances that historically suggest a pullback may be overdue. Annualised volatility of nearly 62% underscores how quickly sentiment can shift.
From July 15, Bayer enters a quiet period ahead of its half-year results, due on August 7, limiting the flow of company commentary. That leaves traders to weigh two competing storylines: the Apollo transaction, expected to close in the third quarter, and the mounting pressure on pharmaceutical margins from Berlin.
Bayer at a turning point? This analysis reveals what investors need to know now.
Industry Warnings and Transitional Relief
The German pharmaceutical industry has reacted with alarm to the new law. Han Steutel, president of the industry association, warned that the higher rebate will damage investment conditions for research and production in Germany, and that some companies may delay or forgo launching new drugs in the country. The government has offered transitional relief: certain exemptions from the additional discount will apply until January 1, 2027, and an interministerial working group is tasked with producing legally sound implementation proposals by the end of September 2026.
For Bayer, the immediate financial impact of the regulatory change will not be fully visible until coming quarterly reports. Meanwhile, the stock’s dual engines — a €3 billion vote of confidence from Apollo and a narrowing but still uncertain legal horizon in the US — must now contend with a freshly tightened pricing regime at home. With limited news flow during the quiet period, the August earnings release and the settlement hearing two weeks later will be the next major signposts for shareholders.
Ad
Bayer Stock: New Analysis - 12 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
